# US 2016/0355508 A1 · Polycyclic estrogen receptor modulators and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355508 A1
- Document ID: US20160355508A1
- Status: Published application
- Kind: A1
- Application number: 14/851,215
- Filed: 2014-03-13
- Published: 2016-12-08
- Earliest claimed: 2013-03-14
- Assignees: Genentech, Inc.
- Applicants: Seragon Pharmaceuticals, Inc.
- Inventors: Nicholas D. Smith; Steven P. Govek; Mehmet Kahraman; Celine Bonnefous; Jackaline D. Julien
- Web page: https://patentgrep.com/patent/US20160355508A1

## CPC

- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/30: Oestrogens
- A61P 5/32: Antioestrogens
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/08: of the prostate
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/06: Antimigraine agents
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/32: Alcohol-abuse
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C07D 211/14: with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- C07D 211/34: with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 213/55: Acids; Esters
- C07D 213/61: Halogen atoms or nitro radicals
- C07D 213/64: attached in position 2 or 6
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 233/56: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D 233/60: with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
- C07D 257/04: Five-membered rings
- C07D 261/08: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 263/32: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 275/02: not condensed with other rings
- C07D 277/30: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 295/155: with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 403/10: linked by a carbon chain containing aromatic rings
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 409/10: linked by a carbon chain containing aromatic rings
- C07D 417/10: linked by a carbon chain containing aromatic rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.

## Claims

### Claim 1

A compound of Formula (VII), or a pharmaceutically acceptable salt, or N-oxide thereof:
wherein,
ring A is 3-7 membered monocyclic C2-C6 heterocycloalkyl, 5-membered monocyclic heteroaryl, or 6-membered monocyclic heteroaryl;
each Ra is independently selected from the group consisting of H, halogen, —NR7R8, —CN, —OH, —OR9, —SR8, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6fluoroalkyl, and substituted or unsubstituted C1-C6 heteroalkyl;
m is 0, 1, 2, 3, or 4;
ring B is phenyl, indanyl, indenyl, naphthyl, 5-membered monocyclic heteroaryl, 6-membered monocyclic heteroaryl, or 8-, 9- or 10-membered bicyclic heteroaryl;
each Rb is independently selected from the group consisting of H, halogen, —NR7R8, —CN, —OH, —OR9, —SR8, —S(═O)R9, —S(═O)2R9, —NHS(═O)2R9, —S(═O)2N(R8)2, —C(═O)R9, —OC(═O)R9, —CO2R8, —OCO2R9, —C(═O)N(R8)2, —OC(═O)N(R8)2, —NR7C(═O)N(R8)2, —NR7C(═O)R9, —NR7C(═O)OR9, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C2-C6alkenyl, substituted or unsubstituted C2-C6alkynyl, substituted or unsubstituted C1-C6fluoroalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted phenyl and substituted or unsubstituted monocyclic heteroaryl;
n is 0, 1, 2, 3, or 4;
each Rc is independently selected from the group consisting of H, halogen, —CN, —OH, —OR9, C1-C6alkyl, or C1-C6fluoroalkyl;
p is 0, 1, 2, 3 or 4;
R5 is H, C1-C4 alkyl, or halogen;
R6 is H, C1-C4 alkyl, or halogen;
R1 is —C(═O)—Z, a carboxylic acid bioisostere, or a substituted or unsubstituted N-containing C2-C8 heterocycloalkyl;
Z is —OH, —OR9, —NR7R8, —NR7S(═O)2R9, —NHOH or —NR7OR9;
R2 is halogen, —CN, —NO2, —SR9, C1-C6alkyl, C1-C6fluoroalkyl, C1-C6 deuteroalkyl, C3-C6 cycloalkyl, —C1-C4alkylene-W, —C1-C4fluoroalkylene-W, —C3-C6 cycloalkylene-W;
W is hydroxy, halogen, —CN, —NO2, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy, C1-C6 haloalkoxy, and C3-C6 cycloalkyl;
each R3 is independently selected from the group consisting of H, halogen, —CN, C1-C6alkyl, C1-C6 fluoroalkyl, and C1-C6 heteroalkyl;
q is 0, 1, 2, 3 or 4;
R4 is H, halogen, —CN, —OH, —OR9, —SR8, —S(═O)R9, —S(═O)2R9, —NHS(═O)2R9, —S(═O)2N(R8)2, —C(═O)R9, —OC(═O)R9, —CO2R8, —C(═O)N(R8)2, —OC(═O)N(R8)2, C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6fluoroalkyl, or C1-C6heteroalkyl;
each R7 is independently H or C1-C6alkyl;
each R8 is independently selected from H, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C2-C6 alkenyl, substituted or unsubstituted C2-C6 alkynyl, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted C1-C6 heteroalkyl, substituted or unsubstituted C3-C10 cycloalkyl, substituted or unsubstituted C2-C10 heterocycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted monocyclic heteroaryl, or substituted or unsubstituted benzyl;
each R9 is independently selected from substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C1-C6fluoroalkyl, substituted or unsubstituted C3-C10cycloalkyl, substituted or unsubstituted C2-C10heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl and substituted or unsubstituted benzyl.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
ring A is 3-7 membered monocyclic N-containing C2-C6 heterocycloalkyl, N-containing 5-membered monocyclic heteroaryl, or N-containing 6-membered monocyclic heteroaryl; and
ring B is phenyl, indanyl, indenyl, naphthyl, 5-membered monocyclic heteroaryl, 6-membered monocyclic heteroaryl, or 8-, 9- or 10-membered bicyclic heteroaryl.

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
ring A is aziridinyl, azetindinyl, pyrrolidinyl, piperidinyl, azepanyl, imidazolidinyl, pyrazolidinyl, morpholinyl, thiomorpholinyl, piperazinyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, or triazinyl; and
ring B is phenyl, naphthyl, indanyl, indenyl, furanyl, thienyl, oxazolyl, thiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, inolizinyl, azainolizinyl, indolyl, azaindolyl, indazolyl, azaindazolyl, benzimidazolyl, azabenzimidazolyl, benzotriazolyl, azabenzotriazolyl, benzoxazolyl, azabenzoxazolyl, benzisoxazolyl, azabenzisoxazolyl, benzofuranyl, azabenzofuranyl, benzothienyl, azabenzothienyl, benzothiazolyl, azabenzothiazolyl, or purinyl.

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R1 is —C(═O)—Z,
Z is —OH, —OR9, or —NR7R8.

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

The compound of claim of 1, wherein the compound of Formula (VII) has the following structure of Formula (VIII) or Formula (IX):
or is a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 16)

The compound of claim 16, or a pharmaceutically acceptable salt thereof, wherein:
ring A is aziridinyl, azetindinyl, pyrrolidinyl, piperidinyl, azepanyl, imidazolidinyl, pyrazolidinyl, morpholinyl, thiomorpholinyl, piperazinyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, or triazinyl.

### Claim 19 (depends on 16)

The compound of claim 16, or a pharmaceutically acceptable salt thereof, wherein:
ring A is C-linked 3-7 membered monocyclic N-containing C2-C6heterocycloalkyl, C-linked N-containing 5-membered monocyclic heteroaryl, or C-linked N-containing 6-membered monocyclic heteroaryl.

### Claim 20 (depends on 19)

The compound of claim 19, or a pharmaceutically acceptable salt thereof, wherein:

### Claim 21 (depends on 16)

The compound of claim 16, or a pharmaceutically acceptable salt thereof, wherein:
ring A is N-linked 3-7 membered monocyclic N-containing C2-C6heterocycloalkyl, or N-linked N-containing 5-membered monocyclic heteroaryl.

### Claim 22 (depends on 21)

The compound of claim 21, or a pharmaceutically acceptable salt thereof, wherein:

### Claim 23 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

### Claim 24 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

### Claim 25 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

### Claim 26 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

### Claim 27 (depends on 1)

The compound claim 1, or a pharmaceutically acceptable salt thereof, wherein:

### Claim 28 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

### Claim 29 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

### Claim 30 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
R5 is H;
R6 is H.

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R2 is C1-C6 alkyl or C3-C6 cycloalkyl.

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37 (depends on 34)

The compound of claim 34, or a pharmaceutically acceptable salt thereof, wherein:
R2 is —CH2CH3.

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40 (depends on 34)

The compound of claim 34, or a pharmaceutically acceptable salt thereof, wherein:
R2 is cyclobutyl.

### Claim 41 (depends on 1)

The compound of claim 1, wherein the compound of Formula (I) has the following structure of Formula (X):
or is a pharmaceutically acceptable salt thereof.

### Claim 42 (depends on 41)

The compound of claim 41, wherein the compound of Formula (X) has the following structure of Formula (XI):
wherein,
is N-linked 3-7 membered monocyclic N-containing C2-C6heterocycloalkyl or N-linked N-containing 5-membered monocyclic heteroaryl;
or is a pharmaceutically acceptable salt thereof.

### Claim 43 (depends on 41)

The compound of claim 41, wherein the compound of Formula (X) has the following structure of Formula (XII):
is C-linked 3-7 membered monocyclic N-containing C2-C6heterocycloalkyl, C-linked N-containing 5-membered monocyclic heteroaryl, or C-linked N-containing 6-membered monocyclic heteroaryl;
or is a pharmaceutically acceptable salt thereof.

### Claim 44 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
Rb is H, F, Cl, —CN, —OH, —OR9, —SR8, —S(═O)R9, —S(═O)2R9, C1-C6alkyl, C1-C6fluoroalkyl, or C1-C6heteroalkyl;
R4 is H, F, Cl, —CN, —OH, —OR9, —SR8, —S(═O)R9, —S(═O)2R9, C1-C6alkyl, C1-C6fluoroalkyl, or C1-C6heteroalkyl.

### Claim 45 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein
Rb is H, F, Cl, —CN, —OH, —OCH3, —OCH2CH3, —OCF3, —S(═O)2CH3, —CH3, —CF3, or —CH2OH;
R4 is H, F, Cl, —CN, —OH, —OCH3, —OCH2CH3, —OCF3, —S(═O)2CH3, —CH3, —CF3, or —CH2OH.

### Claim 46 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
each Ra is independently selected from the group consisting of H, halogen, —CN, —OH, —OR9, C1-C6alkyl, C1-C6fluoroalkyl, and C1-C6heteroalkyl;
m is 0 or 1.

### Claim 47 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
m is 0.

### Claim 48 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
p is 0.

### Claim 49 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
q is 0.

### Claim 50 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R1 is —C(═O)—OH.

### Claim 51

A compound that is:
(E)-3-(4-((E)-1-(4-(1H-Pyrazol-4-yl)phenyl)-2-cyclobutyl-2-phenylvinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-(2-Chloro-4-fluorophenyl)-1-(4-(thiazol-5-yl)phenyl)but-1-en-1-yl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(4-(1H-Pyrazol-4-yl)phenyl)-2-(2-chloro-4-cyanophenyl)-2-cyclobutylvinyl)phenyl) acrylic acid;
(E)-3-(4-((E)-2-(2-Chloro-4-methoxyphenyl)-2-cyclobutyl-1-(4-morpholinophenyl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-(2-Chloro-4-cyanophenyl)-2-cyclobutyl-1-(4-(thiazol-5-yl)phenyl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(4-(1H-Pyrazol-5-yl)phenyl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(3-(1H-Pyrazol-5-yl)phenyl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-Phenyl-1-(4-(thiazol-2-yl)phenyl)but-1-en-1-yl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-Phenyl-1-(4-(thiazol-5-yl)phenyl)but-1-en-1-yl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-Phenyl-1-(4-(thiazol-4-yl)phenyl)but-1-en-1-yl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-Phenyl-1-(3-(thiazol-2-yl)phenyl)but-1-en-1-yl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-Phenyl-1-(3-(thiazol-4-yl)phenyl)but-1-en-1-yl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-Cyclobutyl-2-phenyl-1-(4-(thiazol-5-yl)phenyl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-Phenyl-1-(4-(pyridin-3-yl)phenyl)but-1-en-1-yl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(4-(Isothiazol-4-yl)phenyl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(4-Morpholinophenyl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(4-(1H-Imidazol-1-yl)phenyl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(4-(Oxazol-5-yl)phenyl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(4-(1-Methyl-1H-pyrazol-4-yl)phenyl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(2-Fluoro-4-(thiazol-5-yl)phenyl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(3-Fluoro-4-(thiazol-5-yl)phenyl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(4-(1H-Pyrazol-4-yl)phenyl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(4-(4-Methylpiperazin-1-yl)phenyl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-Phenyl-1-(4-(piperidin-1-yl)phenyl)but-1-en-1-yl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-Cyclobutyl-2-phenyl-1-(5-(thiazol-5-yl)pyridin-2-yl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(3-(1H-Pyrazol-4-yl)phenyl)-2-cyclobutyl-2-phenylvinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-Cyclobutyl-1-(4-(isoxazol-3-yl)phenyl)-2-phenylvinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-(3-Chloropyridin-4-yl)-1-(4-(thiazol-5-yl)phenyl)but-1-en-1-yl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-(2-Chlorophenyl)-1-(4-(thiazol-5-yl)phenyl)but-1-en-1-yl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-(3-Methoxyphenyl)-1-(4-(thiazol-5-yl)phenyl)but-1-en-1-yl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-(Benzofuran-5-yl)-1-(4-(thiazol-5-yl)phenyl)but-1-en-1-yl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-(4-Methylthiophen-3-yl)-1-(4-(thiazol-5-yl)phenyl)but-1-en-1-yl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-(2-Chloro-4-fluorophenyl)-2-cyclobutyl-1-(4-(thiazol-5-yl)phenyl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-(3-Chloropyridin-4-yl)-2-cyclobutyl-1-(4-(thiazol-5-yl)phenyl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-Cyclobutyl-2-(4-methylthiophen-3-yl)-1-(4-(thiazol-5-yl)phenyl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-(2-Chloro-4-fluorophenyl)-2-cyclobutyl-1-(4-morpholinophenyl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(4-(1H-Pyrazol-4-yl)phenyl)-2-(2-chloro-4-fluorophenyl)-2-cyclobutylvinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(4-(1H-Pyrazol-4-yl)phenyl)-2-cyclobutyl-2-(4-methylthiophen-3-yl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-Cyclobutyl-2-(6-methoxy-4-methylpyridin-3-yl)-1-(4-morpholinophenyl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(4-(1H-Pyrazol-4-yl)phenyl)-2-cyclobutyl-2-(3-methylpyridin-2-yl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(4-(1H-Pyrazol-4-yl)phenyl)-2-cyclobutyl-2-(3-fluoropyridin-2-yl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(4-(1H-Pyrazol-4-yl)phenyl)-2-(3-chloropyridin-2-yl)-2-cyclobutylvinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-(3-Chloropyridin-2-yl)-2-cyclobutyl-1-(4-morpholinophenyl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(4-(1H-Pyrazol-4-yl)phenyl)-2-(4-chloro-2-cyanophenyl)-2-cyclobutylvinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-(2-Chloro-4-cyanophenyl)-2-cyclobutyl-1-(4-morpholinophenyl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-(4-Chloro-2-cyanophenyl)-2-cyclobutyl-1-(4-morpholinophenyl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-Cyclobutyl-2-(4-methoxy-2-methylphenyl)-1-(4-morpholinophenyl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-(2-Chloro-4-(trifluoromethyl)phenyl)-2-cyclobutyl-1-(4-morpholinophenyl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(4-(2H-Tetrazol-5-yl)phenyl)-2-(2-chloro-4-fluorophenyl)-2-cyclobutylvinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(4-(2H-Tetrazol-5-yl)phenyl)-2-(2-chloro-4-methoxyphenyl)-2-cyclobutylvinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(4-(1H-Pyrazol-4-yl)phenyl)-2-(2-chloro-4-methoxyphenyl)-2-cyclobutylvinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(4-(1H-Pyrazol-4-yl)phenyl)-2-(2-chloro-4-(trifluoromethoxy)phenyl)-2-cyclobutylvinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-(2-Chloro-4-methoxyphenyl)-2-cyclobutyl-1-(4-(thiazol-5-yl)phenyl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-Cyclobutyl-2-(4-methoxy-2-methylphenyl)-1-(4-(thiazol-5-yl)phenyl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(4-(1H-Pyrazol-4-yl)phenyl)-2-(2-chloro-4-(trifluoromethyl)phenyl)-2-cyclobutylvinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-(2-Chloro-4-fluorophenyl)-2-cyclobutyl-1-(4-(pyridin-4-yl)phenyl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-2-cyclobutyl-1-(4-morpholinophenyl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(4-(1H-Pyrazol-4-yl)phenyl)-2-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-2-cyclobutylvinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-(3-Chloro-5-(trifluoromethyl)pyridin-2-yl)-2-cyclobutyl-1-(4-(thiazol-5-yl)phenyl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-(2-Chloro-4-fluorophenyl)-1-(2-cyano-4-morpholinophenyl)-2-cyclobutylvinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-1-(4-(1H-Pyrazol-4-yl)phenyl)-2-cyclobutyl-2-(6-methoxy-4-methylpyridin-3-yl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-(4-Chloro-2-cyanophenyl)-2-cyclobutyl-1-(4-(thiazol-5-yl)phenyl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-Cyclobutyl-1-(4-(4-methylpiperidin-1-yl)phenyl)-2-phenylvinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-Cyclobutyl-2-phenyl-1-(4-(piperazin-1-yl)phenyl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-Cyclobutyl-2-phenyl-1-(4-(pyridin-4-yl)phenyl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-Cyclobutyl-1-(4-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)phenyl)-2-phenylvinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-Cyclobutyl-1-(4-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)phenyl)-2-(4-methylthiophen-3-yl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-(2-Chloro-4-fluorophenyl)-2-cyclobutyl-1-(4-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)phenyl)vinyl)phenyl)acrylic acid;
(E)-3-(4-((E)-2-Cyclobutyl-1-(4-(1-(2-(dimethylamino)ethyl)-1H-pyrazol-4-yl)phenyl)-2-phenylvinyl)phenyl)acrylic acid; or
5-((E)-4-((E)-1-(4-(1H-Pyrazol-4-yl)phenyl)-2-(2-chloro-4-fluorophenyl)-2-cyclobutylvinyl)styryl)-2H-tetrazole;
or a pharmaceutically acceptable salt thereof.

### Claim 52 (depends on 1)

A pharmaceutical composition comprising a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 53 (depends on 52)

The pharmaceutical composition of claim 52, wherein the pharmaceutical composition is formulated for intravenous injection, subcutaneous injection, oral administration, or topical administration.

### Claim 54 (depends on 52)

The pharmaceutical composition of claim 52, wherein the pharmaceutical composition is a tablet, a pill, a capsule, a liquid, a suspension, a gel, a dispersion, a solution, an emulsion, an ointment, or a lotion.

### Claim 55

(canceled)

### Claim 56

(canceled)

### Claim 57

(canceled)

### Claim 58

(canceled)

### Claim 59

(canceled)

### Claim 60

(canceled)

### Claim 61

(canceled)

### Claim 62 (depends on 1)

A method of treating cancer in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of claim 1 wherein the cancer is breast cancer, ovarian cancer, endometrial cancer, prostate cancer, lung cancer or uterine cancer.
